Oliva Therapeutics Forges Long-Term Partnership with Rio Biopharmaceuticals
16 June 2023 - - US-based healthcare company Oliva Therapeutics, LLC has forged a long-term partnership with Rio Biopharmaceuticals, Inc., a subsidiary of the EMS S/A Pharma family of companies, for the exclusive North American supply and distribution rights to a multi-product portfolio, the company said.

The collaboration expands and diversifies the Oliva product portfolio while representing the first commercialization into the United States and Canadian markets for Rio Biopharmaceuticals, expanding upon the organization's vast global presence.

The portfolio anticipates initial product commercialization in 2024 followed by additional launches over the succeeding 24-months.

Oliva Therapeutics, LLC is a healthcare company focused on integrity and rooted in family.

In an ever-changing world, Oliva aims to bring clarity and simplicity to patients, physicians, and caregivers through our high-quality products and services.

Rio Biopharmaceuticals Inc is the US subsidiary of EMS S/A, the largest pharmaceutical company in Brazil.

EMS S/A currently markets over 500 generic and innovative products in Brazil and internationally.

Rio will be bringing selected products from this extensive portfolio to the US market following US Food and Drug Administration Approval.